Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Korean GlomeuloNephritis Study Group, Korean Society of Nephrology, Seoul, Republic of Korea.
PLoS One. 2019 Apr 19;14(4):e0215217. doi: 10.1371/journal.pone.0215217. eCollection 2019.
Although C1q nephropathy (C1qN) was introduced three decades ago, the clinical significance and renal outcomes of C1qN remain unclear. This study aimed to evaluate the clinical characteristics of C1qN, including renal outcomes, by performing a matched comparison within a multicenter cohort. We enrolled 6,413 adult patients who underwent kidney biopsy between January 2000 and January 2018 at three tertiary hospitals in Korea. We compared the clinical characteristics of 23 patients with C1qN with those of patients with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD) who were matched by age, sex, diabetic status, and a period of biopsy. Histological and clinical parameters in patients with C1qN were also evaluated according to the different pathological phenotypes. For a mean follow-up period of 92 months, 4 patients with C1qN (17.4%) developed end-stage renal disease (ESRD). None of the matched patients with MCD had ESRD, but 7 (30.4%) of patients with FSGS progressed to ESRD, which was not different from that of C1qN patients (p = 0.491). Laboratory and pathological findings, except segmental glomerulosclerosis, were not notably different between FSGS and C1qN. The presence of segmental glomerulosclerosis, mesangial hypercellularity, and podocyte effacement did not affect both the short- and long-term renal outcomes in patients with C1qN. Our study showed that the renal outcomes of C1qN are comparable with those of FSGS, and not with MCD. Specific pathological findings, including segmental glomerulosclerosis in C1qN, were not associated with renal outcomes, which may suggest homogeneity in the clinical features of C1qN.
虽然 C1q 肾病(C1qN)被提出已有三十年,但 C1qN 的临床意义和肾脏结局仍不清楚。本研究旨在通过在多中心队列中进行匹配比较来评估 C1qN 的临床特征,包括肾脏结局。我们纳入了 2000 年 1 月至 2018 年 1 月期间在韩国三家三级医院接受肾活检的 6413 名成年患者。我们将 23 名 C1qN 患者的临床特征与年龄、性别、糖尿病状态和活检时期相匹配的局灶节段性肾小球硬化症(FSGS)或微小病变性肾病(MCD)患者的临床特征进行了比较。根据不同的病理表型,还评估了 C1qN 患者的组织学和临床参数。在平均 92 个月的随访期间,4 名 C1qN 患者(17.4%)发展为终末期肾病(ESRD)。没有 MCD 的匹配患者发生 ESRD,但 7 名(30.4%)FSGS 患者进展为 ESRD,与 C1qN 患者无差异(p=0.491)。除节段性肾小球硬化外,FSGS 和 C1qN 之间的实验室和病理发现没有明显差异。节段性肾小球硬化、系膜细胞增生和足细胞脱落的存在并未影响 C1qN 患者的短期和长期肾脏结局。我们的研究表明,C1qN 的肾脏结局与 FSGS 相当,而与 MCD 不同。C1qN 中包括节段性肾小球硬化在内的特定病理发现与肾脏结局无关,这可能表明 C1qN 的临床特征具有同质性。